Blogs

Latest Blogs

[wd_asp id=2]

Antibody‑Drug Conjugates (ADCs): The Tipping Point

May 28, 2026

The field of antibody-drug conjugates (ADCs) is entering an exciting era, and there is no shortage of writing today about where this modality is headed:…

Validating Immunity: How ELISpot Data Shaped the AELIX-003 HIV Cure Trial

July 2, 2025

We are proud to share our laboratory’s role in a landmark clinical study published in Nature Communications, titled “Safety, immunogenicity…

From Pathways to Proof: Targeted Phosphoproteomics and PTM Analysis with LC-MS/MS

June 18, 2025

Quadrupole mass spectrometry (LC-MS/MS) has long established itself as the workhorse of bioanalysis for small molecules, valued for its high…

Establishing Biosimilarity: Regulatory and Scientific Expectations

June 5, 2025

A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…

Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures

May 15, 2025

We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…

Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective

May 8, 2025

The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…

Building a bioanalytical workflow for a vaccine study: The key assays and considerations

March 12, 2025

The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…